Phoenix Children’s Hospital’s Institutional Biosafety Committee (IBC) is a federally required panel for the review and approval of all research activities involving recombinant biological materials. IBC’s are mandated and regulated by the National Institutes of Health Office of Science Policy and subject to the requirements set forth in the NIH Guidelines for Research Involving Recombinant DNA Molecules.
The committee is comprised of representatives of the PCH research community, staff, and 2 community members otherwise unaffiliated with PCH. The IBC membership represents collective expertise and research experience in recombinant DNA, infectious agents, toxins, and biological safety.
The PCH IBC meets several times per year on an as-needed basis. All meetings are held at Phoenix Children's Hospital. Upcoming meeting dates are as follow:
- Mock Protocol Review - Wednesday, August 30, 2017, 12:00 PM (AZ time).